Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (PODD) delivers innovative diabetes management solutions through its flagship Omnipod® insulin pump system. This page aggregates official news and developments about the company's medical device innovations, financial performance, and strategic initiatives.
Investors and healthcare professionals will find timely updates including quarterly earnings reports, product launch announcements, regulatory milestones, and partnership agreements. All content is sourced directly from verified corporate communications to ensure accuracy.
Key coverage areas include FDA clearances for new devices, clinical study results, international market entries, and technology partnerships enhancing insulin delivery systems. The resource is particularly valuable for tracking advancements in tubeless pump technology and automated insulin dosing integrations.
Bookmark this page for streamlined access to Insulet's latest developments in diabetes care innovation. Check regularly for updates that may impact long-term growth strategies or patient care standards.
Insulet Corporation (NASDAQ:PODD) has priced a $500 million senior secured term loan B facility and a $60 million senior secured revolving facility. The term loan will be issued at 99.75% of the aggregate principal amount, bearing interest at LIBOR plus 3.25% with a 0.50% LIBOR floor. The revolving loan interest will range from LIBOR plus 2.75% to 3.25%, depending on the company's leverage ratio. Proceeds will be utilized for general corporate purposes, including retiring debt and funding investments. Closing is subject to customary conditions.
Insulet Corporation (NASDAQ:PODD) has announced the syndication of new senior secured credit facilities, which includes a revolving facility and a term loan B facility. The completion of these facilities will depend on lender commitments and market conditions. The proceeds from these credit facilities will be utilized for general corporate purposes, including debt retirement and funding investments. Morgan Stanley is leading the transaction as the arranger and active bookrunner.
Insulet Corporation (NASDAQ: PODD) plans to release its financial results for Q1 2021 on May 6, 2021, after market close. The announcement will be followed by a conference call at 4:30 p.m. ET. Investors can access the live call via the Company's Investor Relations website or by phone. Insulet is recognized for its Omnipod brand, focusing on innovative tubeless insulin pump technology aimed at simplifying life for individuals with diabetes.
Insulet Corporation (NASDAQ: PODD) reported positive results from the pivotal trial of its Omnipod® 5 Automated Insulin Delivery System. The study showcased significant improvements in glycemic control for type 1 diabetes patients aged 6-70, with HbA1c levels reduced from 7.16% to 6.78% in adults and from 7.67% to 6.99% in children. The results were presented at ENDO 2021, indicating the system's safety and effectiveness across age groups. The Omnipod 5, recognized for automating insulin delivery, is expected to launch in limited release in H1 2021.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will host an investor webcast on March 20, 2021, at 12:30 p.m. ET. This event will focus on the Omnipod 5 pivotal trial data for adults and adolescents presented at ENDO 2021. The webcast will feature a presentation and an interactive Q&A session with sell-side analysts. Investors can access the call via Insulet's Investor Relations website, where it will be archived for future reference. Insulet is committed to improving diabetes management through its innovative Omnipod product platform.
Insulet Corporation (NASDAQ: PODD) reported financial results for 2020, achieving revenues of $904.4 million, a 22.5% increase from the previous year. The Omnipod System generated $834.9 million in revenue, with U.S. sales rising 25.3%. However, the gross margin decreased to 64.4%, and net income fell to $6.8 million, down from $11.6 million in 2019. For 2021, the company forecasts revenue growth of 15% to 20%. Strategic highlights include the completion of the pivotal study for the Omnipod 5, set for commercial launch in 2021.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced participation in three virtual investor conferences. Key dates include:
- Citi 2021 Healthcare Conference: February 25, 2021, at 9:50 AM ET
- Raymond James 42nd Annual Conference: March 1, 2021, at 8:20 AM ET
- Cowen 41st Annual Conference: March 2, 2021, at 9:10 AM ET
Live audio webcasts will be available on their investor site, with replays post-conference.
Insulet Corporation (NASDAQ: PODD) has announced the launch of the Omnipod DASH Insulin Management System in Canada. The Omnipod DASH features a touchscreen Personal Diabetes Manager (PDM) that wirelessly controls a tubeless, waterproof Pod, offering up to 72 hours of continuous insulin delivery. Insulet plans a province-by-province rollout throughout 2021, aligning with provincial health program reimbursements. Feedback from early users highlights the system's ease of use and potential for more effective diabetes management.
Insulet Corporation (NASDAQ: PODD) announced it will release its financial results for Q4 and the full year of 2020 on February 23, 2021, after the market closes. A conference call will follow at 4:30 p.m. ET to discuss these results. Insulet is known for its innovative Omnipod Insulin Management System, a tubeless insulin pump designed to enhance diabetes management with its simple and wearable technology, allowing up to three days of continuous insulin delivery without needles.
Insulet Corporation (NASDAQ: PODD) will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2021, at 9:10 a.m. Eastern Time. This event highlights Insulet's innovative Omnipod Insulin Management System, a tubeless insulin pump designed to simplify diabetes management. The system offers up to three days of continuous insulin delivery without the need for needles. A live audio webcast will be available, with a replay accessible post-event. For more information, visit www.insulet.com.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
